DBV Technologies S.A. (DBVT)

DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low – Time to Sell?

DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis

DBV Technologies to Participate in Upcoming September Investor Conferences

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

DBV Technologies Q2 Earnings Call Highlights

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026